H3 Biomedicine

H3 Biomedicine Announces Presentation of Four Abstracts at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Read More

Intron Retention Is a Hallmark and Spliceosome Represents a Therapeutic Vulnerability in Aggressive Prostate Cancer

The role of dysregulation of mRNA alternative splicing (AS) in the development and progression of solid tumors remains to be… Read More

Correlation of the in vitro Biotransformation of H3B-6527 in Dog and Human Hepatocytes With the in vivo Metabolic Profile of 14 C-H3B-6527 in a Dog Mass Balance Study

1. H3B-6527 is an orally available covalent small molecule inhibitor of FGFR4 undergoing evaluation in adults with hepatocellular carcinoma. Absorption,… Read More

Small Molecule Inhibition of CPS1 Activity Through an Allosteric Pocket

Carbamoyl phosphate synthetase 1 (CPS1) catalyzes the first step in the ammonia-detoxifying urea cycle, converting ammonia to carbamoyl phosphate under… Read More

Chutes & Ladders

Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Read More

Antonio Gualberto starts post-Kura career at Eisai subsidiary H3

Days after Kura Oncology announced the departure of co-founder Antonio Gualberto, we finally know where he wound up. Read More

Up and down the ladder: The latest comings and goings

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Read More

BioSpace Movers & Shakers

H3, a subsidiary of Eisai Co., named Antonio Gualberto as its new CMO. Gualberto will oversee global clinical research &… Read More

Eisai subsidiary names Antonio Gualberto as CMO

H3 Biomedicine, the USA-based precision medicine subsidiary of Japanese drugmaker Eisai, has named industry Read More

Eisai unit H3 Biomedicine poaches Kura Oncology founder as CMO

Antonio Gualberto, M.D., Ph.D., helped found early-stage biotech Kura Oncology and ran its R&D as chief medical officer. Read More